Todd Bunch
About Todd Bunch
Todd Bunch is the Group Director of Toxicology at Bristol-Myers Squibb, with over 15 years of experience at the company.
Group Director, Toxicology at Bristol-Myers Squibb
Todd Bunch serves as the Group Director of Toxicology at Bristol-Myers Squibb. In this role, he leads the Nonclinical Safety Evaluation and Veterinary Sciences department. Based in Princeton, New Jersey, Todd contributes significantly to the company’s nonclinical safety evaluation efforts, ensuring the safety of pharmaceutical products before they proceed to clinical trials. His extensive background in toxicology drives forward innovative safety assessments and safety risk management practices.
Education and Expertise in Pharmacology and Toxicology
Todd Bunch holds a Doctor of Philosophy (PhD) in Pharmacology and Toxicology from Virginia Commonwealth University, where he studied from 1988 to 1993. This advanced degree signifies his deep understanding and specialized knowledge in the field. Additionally, Todd earned a Bachelor of Arts (BA) in Chemistry from Williams College, having studied from 1984 to 1988. His academic credentials provide a strong scientific foundation, which he applies in his role at Bristol-Myers Squibb.
Career at Bristol-Myers Squibb
Todd Bunch has been with Bristol-Myers Squibb for over 15 years, beginning his tenure in February 2008. Throughout his time with the company, he has spearheaded initiatives within the Nonclinical Safety Evaluation and Veterinary Sciences department. His long-term commitment to the organization underscores his dedication to ensuring the nonclinical safety of pharmaceuticals, playing a crucial role in the development of safe and effective medical treatments.
Responsibilities in Nonclinical Safety Evaluation
In his leadership position at Bristol-Myers Squibb, Todd Bunch oversees the Nonclinical Safety Evaluation and Veterinary Sciences department. His responsibilities include guiding the safety assessment processes for new pharmaceutical compounds, evaluating potential risks, and implementing safety strategies. Todd’s work is integral to advancing the safety profile of drugs before they are tested in human trials, thereby ensuring regulatory compliance and patient safety.